EP Patent

EP3852734A1 — Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness

Assigned to Novaliq GmbH · Expires 2021-07-28 · 5y expired

What this patent protects

The present disclosure provides methods of treatment using ophthalmic compositions, comprising 1-perfluorohexyloctane, which are useful in the treatment of ocular surface damage of the cornea and/or symptoms of dryness.

USPTO Abstract

The present disclosure provides methods of treatment using ophthalmic compositions, comprising 1-perfluorohexyloctane, which are useful in the treatment of ocular surface damage of the cornea and/or symptoms of dryness.

Drugs covered by this patent

Patent Metadata

Patent number
EP3852734A1
Jurisdiction
EP
Classification
—
Expires
2021-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.